Page 265 - Glucose Monitoring Devices

272 CHAPTER 13 Low glucose suspend systems

[26] Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012;35:
1814e6.
[27] Shi L, Shao H, Zhao Y, Thomas NA. Is hypoglycemia fear independently associated
with health-related quality of life? Health and Quality of Life Outcomes 2014;12:
167. https://doi.org/10.1186/s12955-014-0167-3.
[28] Garg SK, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J,
Welsh JB, Kaufman FR. Hypoglycemia begets hypoglycemia: the order effect in the
ASPIRE in-clinic study. Diabetes Technology and Therapeutics March 2014;16(3):
125e30.
[29] Kowalski A. Pathway to artificial pancreas systems revisited: moving downstream. Dia-
betes Care June 2015;38(6):1036e43.
[30] Pickup JC, Viberti GC, Bilous RW, Keen H, Alberti KG, Home PD, Binder C. Safety of
continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autor-
egulation after deliberate cessation of infusion. Diabetologia March 1982;22(3):175e9.
[31] Krzentowski G, Scheen A, Castillo M, Luyckx AS, Lefe `bvre PJ. A 6-hour nocturnal
interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal
consequences and scheme for a prompt return to adequate control. Diabetologia May
1983;24(5):314e8.
[32] Scheen AJ, Krzentowski G, Castillo M, Lefe `bvre PJ, Luyckx AS. A 6-hour nocturnal
interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of
the metabolic deterioration by somatostatin. Diabetologia May 1983;24(5):319e25.
[33] Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and
lispro insulins after interruption of continuous subcutaneous insulin infusion and in
the treatment of acutely decompensated IDDM. Diabetes Care May 1998;21(5):
817e21.
[34] Guerci B, Meyer L, Salle ´ A, Charrie ´ A, Dousset B, Ziegler O, Drouin P. Comparison of
metabolic deterioration between insulin analog and regular insulin after a 5-hour inter-
ruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. The
Journal of Clinical Endocrinology and Metabolism August 1999;84(8):2673e8.
[35] Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin sus-
pension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at
greatest risk. Diabetes Care 2011;34(9):2023e5.
[36] Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, Bla ¨sig S,
Wadien T, Zierow S, Hartmann R, Thomas A. Prevention of hypoglycemia by using low
glucose suspend function in sensor-augmented pump therapy. Diabetes Technology and
Therapeutics November 2011;13(11):1129e34.
[37] Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-
augmented insulin pump therapy and automated insulin suspension vs standard insulin
pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical
trial. Journal of the American Academy of Dermatology 2013;310(12):1240e7.
[38] Ly TT, Nicholas JA, Retterath A, Davis EA, Jones TW. Analysis of glucose responses to
automated insulin suspension with sensor-augmented pump therapy. Diabetes Care July
2012;35(7):1462e5.
[39] Garg S, Brazg RL, Bailey TS, et al. Reduction in duration of hypoglycemia by auto-
matic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technology
and Therapeutics 2012;14:205e9.